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Characterization of new RNA 
polymerase III and RNA polymerase 
II transcriptional promoters in the 
Bovine Leukemia Virus genome
Benoit Van Driessche1,*, Anthony Rodari1,*, Nadège Delacourt1, Sylvain Fauquenoy1, 
Caroline Vanhulle1, Arsène Burny1, Olivier Rohr2,3,† & Carine Van Lint1,†
Bovine leukemia virus latency is a viral strategy used to escape from the host immune system and 
contribute to tumor development. However, a highly expressed BLV micro-RNA cluster has been 
reported, suggesting that the BLV silencing is not complete. Here, we demonstrate the in vivo 
recruitment of RNA polymerase III to the BLV miRNA cluster both in BLV-latently infected cell lines 
and in ovine BLV-infected primary cells, through a canonical type 2 RNAPIII promoter. Moreover, by 
RPC6-knockdown, we showed a direct functional link between RNAPIII transcription and BLV miRNAs 
expression. Furthermore, both the tumor- and the quiescent-related isoforms of RPC7 subunits were 
recruited to the miRNA cluster. We showed that the BLV miRNA cluster was enriched in positive 
epigenetic marks. Interestingly, we demonstrated the in vivo recruitment of RNAPII at the 3′LTR/host 
genomic junction, associated with positive epigenetic marks. Functionally, we showed that the BLV 
LTR exhibited a strong antisense promoter activity and identified cis-acting elements of an RNAPII-
dependent promoter. Finally, we provided evidence for an in vivo collision between RNAPIII and RNAPII 
convergent transcriptions. Our results provide new insights into alternative ways used by BLV to 
counteract silencing of the viral 5′LTR promoter.
Bovine leukemia virus (BLV) is a B-lymphotropic oncogenic deltaretrovirus infecting cattle that shares common 
biological and structural features with the human T-cell leukemia virus I and II (HTLV-I and II) (reviewed in ref. 1,2). 
In the majority of cases, infection is asymptomatic but 30% of BLV-infected animals will develop a persistent 
lymphocytosis and less than 5% will progress to B-cell lymphoma or leukemia, termed enzootic bovine leucosis, 
after a long period of latency characterized by the absence of viral replication3–5. It is widely accepted that BLV 
latency is a viral strategy used to escape from the host immune response contributing to tumor development6. 
Remarkably, BLV can be experimentally inoculated into sheep that always develop leukemia or lymphoma after a 
shorter period of incubation than in cattle, and therefore sheep represent a model to study tumor development7,8.
Transcription of BLV genes initiates at the U3/R junction in the 5′ -long terminal repeat (LTR) and is regulated 
by cellular transcription factors for which several binding sites have been identified in the LTR9–19, by the viral 
transactivator TAXBLV20 and by the chromatin status of the BLV provirus21–25. Indeed, we have previously demon-
strated that the 5′ LTR RNA polymerase II-driven transcriptional repression is due to the epigenetic state of the 5′ 
LTR characterized by weak histone acetylation and DNA CpG hypermethylation associated to closed chromatin 
in a lymphoma-derived BLV-infected L267 ovine cell line harboring a fully competent provirus19,21,25.
Recent publications from two independent laboratories have identified, by bioinformatics analysis and deep 
sequencing, a cluster of 10 micro-RNAs (miRNAs) encoded by the BLV genome26,27. miRNAs are small ~22 
nucleotides RNAs implicated into the regulation of a constantly increasing number of cellular processes and 
expressed by a wide majority of eukaryotes and some DNA viruses (reviewed in ref. 28). Despite the 5′ LTR 
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silencing dogma, these micro-RNAs are highly transcribed through a non-canonical process, suggesting that 
the BLV found an alternative way to express a part of its genome in a latency state likely by using an alternative 
polymerase29.
In the present report, we investigated the in vivo recruitment of the RNAPII and RNAPIII complexes to the 
BLV genome. We demonstrated the recruitment of a bona fide RNA polymerase III at the BLV miRNA cluster 
through a canonical type 2 RNAPIII promoter similar to the one responsible for transfer RNA (tRNA) transcrip-
tion. We also established a direct functional link between BLV miRNAs expression and RNAPIII transcriptional 
activity. Next, we showed that both tumor- and quiescent-related isoforms of RNAPIII were recruited to the 
miRNA cluster and that the miRNA cluster exhibited a profile of positive epigenetic marks (histone acetylation 
and DNA hypomethylation). Interestingly, in addition to the RNAPIII recruitment, we demonstrated an RNAPII 
recruitment at the junction between the 3′ LTR and the host genome which was also associated with positive 
epigenetic marks typical of transcriptionally active promoters. Therefore, we tested the potential promoter activ-
ity of the LTR and demonstrated that this region was able to drive transcription in the antisense orientation 
in the nucleosomal context of episomally replicating constructs through a new RNAPII-dependent promoter. 
Importantly, ChIP-seq experiments performed in a BLV-infected cell line confirmed the high RNAPIII recruit-
ment to the BLV miRNA cluster and the RNAPII occupancy just downstream of this region, suggesting a collision 
phenomenon between these two polymerase machineries and stalling of RNAPII.
Results
The RNA polymerase III is recruited to the miRNA cluster in vivo. Previous studies have provided 
evidence that the BLV miRNAs are transcribed by RNA polymerase III26,27,30. Indeed, Kincaid et al. have identified 
by bioinformatics analyses RNAPIII initiation cis-elements in the BLV miRNA cluster26. Moreover, they have 
shown by mutagenesis analysis that the identified cis-regulatory elements are functional in the context of 293T 
cells transformed with plasmids coding for BLV miRNA30. Finally, it has been shown that the use of α -amanitin 
at a concentration known to specifically inhibit RNAPII but not RNAPIII did not decrease BLV miRNA pro-
duction26,27,30. However today, the presence of a functional RNAPIII at the BLV miRNA cluster has not been 
demonstrated yet. Therefore, we decided to investigate the in vivo recruitment to the BLV provirus of RNAPIII 
by performing chromatin immunoprecipitation (ChIP) assays. For this purpose, we prepared chromatin from 
the latently BLV-infected L267 cell line and immunoprecipitated the largest RNAPIII subunit (RPC1) using a 
specific antibody. As controls, we performed ChIP assays with a purified IgG to measure the aspecific background 
and with an antibody directed against the largest RNAPII subunit (RPB1). Next, purified DNA was amplified by 
real-time quantitative PCR with oligonucleotide primers hybridizing to thirteen specific regions along the BLV 
genome and its host environment (Fig. 1a). As shown in Fig. 1b, we observed recruitment of RPC1 to the BLV 
miRNA cluster, thereby providing the first in vivo evidence that the BLV miRNAs are transcribed by RNAPIII. As 
positive controls, we amplified the immunopurified DNA by real-time quantitative PCR using oligonucleotide 
primers hybridizing in genes encoding the tRNA for the asparagine amino acid and the 5S ribosomal DNA, both 
known to be RNAPIII-transcribed genes (reviewed in ref. 31). Our results showed that RPC1 was recruited to the 
tRNAAsp and the 5S rDNA genes, demonstrating the functionality of the α -RPC1 antibody we used (Fig. 1e,g).
Regarding the recruitment of RNAPII, our previous studies using the L267 cell line failed to demonstrate 
the recruitment of RNAPII to the 5′ LTR, that contains the main transcriptional promoter of BLV genes21. In the 
present study, we confirmed these observations and, as a control, we showed the presence of RNAPII to the first 
exon of the RASA3 gene, the host gene in which the BLV provirus is integrated in the L267 cell line (Fig. 1b). 
Surprisingly, we observed an important recruitment of RNAPII to the miRNA cluster, in agreement with pre-
viously reported ChIP-seq data showing binding of RNAPII near many known RNAPIII genes32. Interestingly, 
RNAPII was also recruited at the junction between the 3′ LTR and the host genome, suggesting that the 3′ LTR may 
also contains an RNAPII-dependent transcriptional promoter as previously described for the related oncogenic 
deltaretrovirus HTLV-I33.
In order to further validate our results, additional ChIP experiments were performed in the YR2 cell line, 
another latently BLV-infected ovine cell line. These cells are considered as a model for defective latency since two 
E- to K-amino acid substitutions in the viral transactivator TAXBLV impair the infectious potential of the inte-
grated provirus34. Using the YR2 cell line, we observed recruitments of RNAPIII and RNAPII to the BLV genome 
similar to those observed in the L267 cell line (Supplementary Fig. S1). However, as opposed to what we observed 
in the L267 cell line, RNAPII was also recruited at the 5′ LTR, confirming our previous results obtained in the YR2 
cell line21 and supporting the deficiency of transactivation mediated by TAXBLV allowing the formation of the 
RNAPII initiation complex but not an efficient transcriptional elongation24,35.
To confirm our results in a more physiological model of BLV-infected cells, we next evaluated the in vivo 
recruitment of RNAPIII to the BLV provirus in peripheral blood mononuclear cells (PBMCs) isolated from a 
BLV-infected sheep that developed leukemia. We demonstrated recruitment of RPC1 to the BLV miRNA cluster 
(Fig. 1c), thereby confirming, in BLV-infected ovine primary cells, the data we obtained in cell lines. These latter 
results also validated the L267 and YR2 cell lines as an appropriate model to further characterize the RNAPIII 
promoter present at the BLV miRNA cluster.
To further evaluate the in vivo RNAPIII recruitment to the BLV miRNA cluster, we assessed the presence of 
other RNAPIII subunits by ChIP assays. As shown in Fig. 1d, we demonstrated that the RPC1, RPC4 and RPC6 
RNAPIII subunits were recruited to the miRNA cluster. Therefore, we formally identified the presence of a bona 
fide RNAPIII transcriptional machinery in the BLV miRNA cluster. As positive controls, we showed recruitment 
of the different RNAPIII subunits to the tRNAAsp and 5S rDNA genes (Fig. 1e,g).
Finally, as the BLV 5′ LTR is known to be regulated by cellular transcription factors, by the viral transactivator 
TAX and by the cellular activation state, we tested whether the BLV 5′ LTR transcriptional activity could modulate 
the recruitment of RNAPIII and RNAPII to the BLV miRNA cluster and to 3′ LTR/host junction. To this end, we 
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carried out ChIP experiments using chromatin from L267LTaxSN cells, a virus-expressing cell line resulting from 
the transduction of the L267 cell line with a retroviral vector allowing the overexpression of the viral transac-
tivator TaxBLV23, or from L267 cells treated with a combination of phorbol 12-myristate 13-acetate (PMA) plus 
ionomycin, one of the most potent activators of BLV genes expression. Since the background levels between the 
two cell lines were different, recruitment of the different proteins was expressed as fold induction compared to the 
IgG control. Our results demonstrated that, following induction of the 5′ LTR transcriptional activity by the PMA/
ionomycin cellular treatment, recruitment of RPC1 to the miRNA cluster was not affected (Fig. 1f). In addition, 
following transactivation of the 5′ LTR by overexpression of TAXBLV in the L267LTaxSN cells, we observed no change 
Figure 1. In vivo binding of RNAPIII to the BLV miRNA cluster. (a) Schematic representation of the BLV 
provirus in latently-infected L267 ovine cells. The localization of the different amplified regions is presented 
with respect to the BLV genome. (b–g) Chromatin prepared from L267 cells (b,d–g), BLV-infected ovine 
PBMCs (c) or L267LTaxSN cells (f) was immunoprecipitated with specific antibodies directed against different 
subunits of the RNAPIII as indicated, the largest subunit of the RNAPII or with an IgG as background 
measurement. Purified DNA was then amplified with oligonucleotide primers hybridizing to either the BLV 
genome, its host cellular surrounding DNA environment (b–d,f) or to the two class III genes encoding 5S rDNA 
(e) and tRNAAsp (g). Results are presented as histograms indicating percentages of immunoprecipitated DNA 
compared to the input DNA (% IP/INP; b–e,g) or indicating fold enrichment above the value obtained with 
IgG, which was arbitrarily assigned the value of 1 (f). Data are the means ± SEM from one representative of at 
least three independent experiments.
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in the recruitment of the RPC1 subunit to the miRNA cluster nor of the RPB1 subunit to the 3′ LTR/host junction 
(Fig. 1f) compared to the data we obtained in absence of TAXBLV in the L267 cells. As expected, we showed an 
increase in RNAPII recruitment to the 5′ LTR due to the transactivation by TAXBLV. On the contrary, we observed 
a large reduction of RNAPII recruitment to the miRNA cluster in both conditions of activation (see Fig. 1f).
Taken together, our results demonstrate that RNAPIII is recruited to the BLV miRNA cluster in vivo and is not 
dependent on the viral 5′ LTR transcriptional state. Moreover, the recruitment of RNAPII occurs at the 3′ LTR/
host junction, suggesting the presence of a so far unidentified RNAPII promoter in this region.
BLV miRNAs expression is impaired by depletion of RPC6. Since RNAPIII is recruited in vivo to the 
miRNA cluster, we next investigated a potential functional link between RNAPIII transcriptional machinery and 
BLV miRNAs expression. With RPC3 and RPC7, the RPC6 subunit has been demonstrated as a member of a sub-
complex which is essential for RNAPIII transcriptional initiation but not for RNAPIII transcriptional elongation 
and termination36. Therefore, we depleted the RNAPIII subunit RPC6 by RNA interference assays using small 
hairpin RNAs (shRNAs) since RPC6 is the only RNAPIII subunit for which RNA interference experiments have 
been performed in mammalian cells37.
To avoid off-target effects of the shRNAs, we used two different shRNAs recognizing distinct target sites in 
the RPC6 mRNA. We first attempted to deplete RPC6 by transfecting or transducing latently BLV-infected L267 
and YR2 cell lines. Unfortunately, due to the low transfection or transduction efficiencies in these cell lines, we 
were unable to show a decrease either in RPC6 protein level or in BLV miRNA transcripts level. Therefore, we 
performed transduction experiments in the 293T cell line, using lentiviral particles containing shRNAs against 
RPC6 or a non-targeting shRNA as control. Transduced cells were then transfected with a plasmid expressing 
the entire miRNA cluster (pmiR). As an internal control for transfection efficiency, cells were cotransfected with 
a plasmid expressing the Firefly luciferase under the control of the Herpes Simplex Virus thymidine kinase pro-
moter (pTK-luc). Forty-eight hours post-transfection, cells were harvested and lysed. Total RNA and protein 
extracts were used in RT-qPCR and western blot experiments to measure BLV miRNAs expression levels and 
RPC6 protein levels, respectively.
Our results showed that, despite the absence of cellular toxicity as evaluated by protein quantification, the 
level of RPC6 decreased by 76% and 77%, respectively, after transduction of the two shRNA against RPC6, in 
comparison with the level after transduction of the non-targeting control shRNA (Fig. 2a). Moreover, we showed 
that both shRNAs directed against the RNAPIII-specific RPC6 subunit decreased expression of BLV-miR-B4-3p 
(Fig. 2b) and BLV-miR-B2-5p (Fig. 2c), the two most abundant viral miRNAs27. These results demonstrate, for 
the first time, a direct functional link between RNAPIII transcriptional activity and BLV miRNAs expression. As 
controls, we showed (i) that the non-targeting shRNA did not affect BLV miRNAs expression (Fig. 2b,c), (ii) that 
the level of the cellular miR-191 (an RNAPII-transcribed miRNA38) was not decreased following RPC6 knock-
down (Fig. 2d) and (iii) that transfection efficiencies were similar between the different conditions as shown by 
the stablility of Firefly luciferase mRNA level (Fig. 2e).
Thus, our results show that BLV miRNAs expression is impaired following knock-downed expression of 
RPC6, a member of a subcomplex essential for RNAPIII transcriptional initiation.
The BLV miRNAs are transcribed from a type 2 RNAPIII promoter. Three different types of RNAPIII 
promoters are known according to the nature and position of specific cis-regulating elements that allow recruit-
ment of specific RNAPIII transcription initiation factors (reviewed in ref. 31,39,40). Interestingly, each type of 
promoter is responsible for the transcription of different class III genes: type 1, 2 and 3 promoters are typical of 5S 
rDNA, tRNAs and small nuclear and nucleolar (i.e. U6 RNA and 7SK RNA) genes, respectively.
To further physically characterize the BLV RNAPIII promoter responsible for BLV miRNAs transcription, we 
assessed the promoter type using ChIP experiments. For this purpose, sonicated chromatin from L267 cells was 
immunoprecipitated with specific antibodies directed against various RNAPIII transcription initiation factors, or 
with a purified IgG to measure aspecific background. As shown in Fig. 3a, transcription initiation factors specific 
for RNA polymerase III were present in the miRNA cluster region of the BLV provirus. More specifically, we 
did not observe recruitment of TFIIIA, a factor known to be associated only with the type 1 RNAPIII promoter. 
Moreover, we demonstrated the recruitment of TFIIIC, a factor present in both type 1 and type 2 RNAPIII pro-
moters31. In addition, we showed that the TFIIIB complex present at the BLV miRNA cluster was composed of 
the Bdp1 and Brf1 subunits in association with TBP, while the Brf2 subunit, specific of the type 3 RNAPIII pro-
moters31, was absent (Fig. 3a).
In order to validate the specificity of the different antibodies, we amplified immunopurified DNA by real-time 
quantitative PCR with oligonucleotide primers hybridizing to the 5S rDNA gene containing a type 1 RNAPIII 
promoter (Fig. 3b), to the tRNAAsp gene containing a type 2 RNAPIII promoter (Fig. 3c) and to the 7SK gene 
containing a type 3 RNAPIII promoter (Fig. 3d). Our results showed that all RNAPIII transcription initiation 
factors were present at the corresponding control regions in accordance with their expected localization, thereby 
validating the specificity of the antibodies used in ChIP experiments.
Taken together, our results demonstrate that the promoter responsible for transcription of the BLV miRNAs 
is a canonical type 2 RNAPIII promoter, as those driving tRNAs transcription, as previously suggested by the 
cis-regulatory elements identified in the miRNA cluster26,30.
The two RNA polymerase III isoforms are recruited to the BLV miRNA cluster. Following a dupli-
cation event in an ancestor of vertebrates, 2 genes (POLR3G and POLR3GL) have been found to encode two iso-
forms of RPC7 (RPC7α and RPC7β , respectively) defining two different RNAPIII complexes41. The first complex, 
containing the RPC7α subunit, is restricted to undifferentiated ES cells and to tumor cells, while the second, 
containing the RPC7β subunit, is ubiquitously expressed and essential for cell growth42.
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In order to investigate whether cell transformation was required for BLV miRNAs transcription, we evaluated 
the in vivo recruitment to the viral miRNA cluster of the two different RNAPIII complexes. To this end, we per-
formed ChIP assays using chromatin obtained from L267 cells and antibodies directed against the RPC7α and 
RPC7β subunits or a purified IgG to measure aspecific immunoprecipitation background. As shown in Fig. 4a, we 
showed that both RPC7α and RPC7β subunits were recruited to the BLV miRNA cluster.
As positive controls, we amplified immunopurified DNA by real-time quantitative PCR with oligonucle-
otide primers hybridizing in three known RNAPIII-dependent genes (5S rDNA, tRNAAsp and 7SK RNA). As 
shown in Fig. 4b, both RPC7α and RPC7β subunits were recruited to these three genes. Similar experiments were 
Figure 2. Knockdown of RPC6 induces a decrease in BLV miRNAs expression. The 293T cell line was 
transduced with lentiviral vectors expressing different shRNAs directed against RPC6 or a non-targeting shRNA 
and then transiently transfected with a plasmid expressing the miRNA cluster (pmiR). Forty-eight hours post-
transfection, total protein and total RNA were extracted. (a) The α -tubulin (upper panel, loading control) 
and RPC6 (lower panel) were immunodetected by western blotting. Relative quantifications are presented as 
percentages of RPC6 level in comparison with the non-targeting shRNA. (b–e) Quantitative real-time RT-
PCR experiments were performed to measure BLV-miR-B4-3p (b), BLV-miR-B2-5p (c), cellular miR-191 
(d) or Firefly luciferase expression (e). Values were normalized using GADPH gene primers. Data are the 
means ± SEM from one representative of at least two independent experiments.
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performed with sonicated chromatin from the YR2 cell line (Supplementary Fig. S2). Interestingly, as opposed 
to what we observed in the L267 cell line, only the RPC7α subunit appeared to be recruited to the BLV miRNA 
cluster and to control RNAPIII-dependent genes in the YR2 cell line, while both subunits are expressed in YR2 
cells (Anne Van den Broeke, personal communication). This unexpected result could possibly be explained by 
a differential recruitment of RPC7α and RPC7β , after cellular transformation, in the L267 cell line compared to 
the YR2 cell line.
Taken together, our results suggest that the two different isoforms of RNAPIII are able to transcribe the BLV 
miRNAs at all stages of the BLV disease, in agreement with previous RNA-seq data showing miRNAs expression 
in transformed and non-transformed cells27.
The BLV miRNA cluster DNA is not methylated. It is known that CpG islands, DNA regions where 
enriched CpG dinucleotides are observed, may modulate transcriptional activity of a nearby promoter, according 
with their methylation status43. In addition, our laboratory has previously demonstrated that DNA methylation 
is an important epigenetic chromatin modification that represses BLV transcription from the 5′ LTR in the true 
latent L267 cell line25. In order to determine whether DNA methylation modulates BLV miRNAs expression, we 
first performed in silico analyses using three different prediction tools (Methprimer, CpGPlot and CpG Island 
Searcher) to identify putative CpG islands in the region of the miRNA cluster. The three prediction tools iden-
tified a CpG island containing the BLV miRNA cluster and spanning a region from nucleotide (nt) + 6342 to 
nt + 6833 (nt + 1 defined as the first nucleotide of the 5′ LTR after retrotranscription). Then, we evaluated the 
DNA methylation status of each CpG dinucleotide of the BLV miRNA cluster in the context of integrated pro-
viruses present in L267 and YR2 cells by treating genomic DNA with sodium bisulfite. Our results showed that, 
except for the third and the fourth CpG located upstream of the first BLV pre-miR, the miRNA cluster was not 
methylated in both the L267 (Fig. 5) and YR2 (Supplementary Fig. S3) cell lines.
In conclusion, our results indicate that the BLV miRNA cluster exhibits an hypomethylated CpG profile, in 
agreement with the high expression level of the BLV miRNAs27.
Figure 3. A type 2 RNAPIII promoter drives BLV miRNAs transcription. Chromatin prepared from L267 
cells was immunoprecipitated with antibodies directed against different RNAPIII transcription initiation factors 
or with an IgG as control. Purified DNA was then amplified with oligonucleotide primers hybridizing either to 
the 5′ LTR, the miRNA cluster or the 3′ LTR/host junction regions (a), either to the type 1 RNAPIII promoter of 
the 5S rDNA gene (b), the type 2 RNAPIII promoter of the tRNAasp gene (c) or to the type 3 RNAPIII promoter 
of the 7SK gene (d). Results are presented as histograms indicating percentages of immunoprecipitated DNA 
compared to the input DNA (% IP/INP). Data are the means ± SEM from one representative of at least three 
independent experiments.
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Epigenetic marks associated with active promoters are present to the miRNA cluster and 
3′LTR/host cellular DNA junction. In order to further characterize the epigenetic environment present at 
the BLV miRNA cluster and 3′ LTR/host cellular DNA junction, we performed ChIP assays using chromatin from 
L267 cells and antibodies directed against histone post-translational modifications or the H2A.Z histone variant. 
As shown in Fig. 6a, we observed the presence, at the level of the miRNA cluster, of acetylated histone H3 (H3Ac), 
acetylated histone H3 lysine 9 (H3K9Ac) and trimethylated lysine 4 histone H3 (H3K4me3), three chromatin 
marks associated with RNAPII- and RNAPIII active promoters44,45. Interestingly, those marks were also present 
at the 3′ LTR/host cellular DNA junction, further supporting the presence of an active promoter in this region. In 
agreement with these results, we did not detect H3K9me3 and H3K27me3, two repressive epigenetic marks asso-
ciated with transcriptional silencing. As positive controls, we showed the presence of these two repressive marks 
at the ZNF12 and HOXD10 promoter regions (Fig. 6b) as previously reported46,47.
Interestingly, our results showed the presence of H3K4me2 and the histone H2A.Z variant, two epigenetic 
marks associated with active promoters and enhancers45 in the three tested regions (Fig. 6a,c). Moreover, we 
observed the presence in the three regions of H3K36me3, a positive epigenetic mark associated with RNAPII 
transcriptional elongation. Remarkably, since the level of H3K36me3 has been previously reported to increase 
within gene bodies45 and since the profile of H3K36me3 shown here was increasing from the 3′ LTR to the 5′ LTR, 
our results were in agreement with the presence of an antisense transcription starting from the 3′ LTR.
Together, our data strongly support the presence of active promoters at the BLV miRNA cluster and at the 
junction between the 3′ LTR and the host genomic region.
The region of RNAPII recruitment in the BLV 3′LTR exhibits antisense promoter activity. The 
in vivo recruitment of RNAPII at the 3′ LTR/host junction (Fig. 1b) and its epigenetic profile characteristic of an 
active promoter (Fig. 6a,c) prompted us to test its potential promoter activity in a nucleosomal context. To this 
end, we decided to use pREP-based episomal reporter constructs containing the EBV replication origin and 
encoding nuclear antigen EBNA-1. Indeed, several studies have reported that pREP-based episomal constructs 
display hallmarks of proper chromatin structure when transiently transfected into cells48,49. Thus, we cloned 
Figure 4. Recruitment of the RPC7α and RPC7β subunits to the BLV miRNA cluster. Chromatin prepared 
from L267 cells was immunoprecipitated with specific antibodies directed against the two isoforms of the RPC7 
subunit or with an IgG as background measurement. Purified DNA was then amplified with oligonucleotide 
primers hybridizing to the 5′ LTR, the miRNA cluster or the 3′ LTR/host junction regions (a) or to class III 
control genes (b). Results are presented as histograms indicating fold enrichments compared to the value 
obtained with IgG to which a value of 1 was assigned. Data are the means ± SEM from one representative of at 
least three independent experiments.
Figure 5. Evaluation of the CpG dinucleotide methylation status of the BLV miRNA cluster. Genomic DNA 
from L267 cells was extracted and treated with sodium bisulfite and the miRNA cluster was amplified by nested 
PCR. These amplified products were cloned in a TA cloning vector and 10 independent clones were sequenced. 
Open and filled circles represent non-methylated and methylated CpG dinucleotides, respectively. The position 
of the 5 BLV-pre-miRs with respect to the miRNA cluster is presented in the lower part of the figure.
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the complete BLV LTR upstream of the luciferase (luc) gene in both the 5′ and 3′ orientations into a modified 
pREP10 episomal vector (pREP-luc). The episomally replicating BLV LTR-luc constructs we generated (named 
pREP-LTR(wt)-S-luc and pREP-LTR(wt)-AS-luc, respectively) were co-transfected into the human B-lymphoid 
Raji cell line with increasing amounts of a BLV Tax expression vector. Forty-hours post-transfection, cells were 
lysed and assayed for luciferase activity (Fig. 7a). The pREP-LTR(wt)-AS-luc construct presented a higher 
(p value = 0.0002) luciferase activity than the pREP-LTR(wt)-S-luc construct, with a 329-fold and 28-fold 
increase of the luciferase activity, respectively, compared to the parental reporter vector pREP-luc. Moreover, Tax 
transactivated both the sense and antisense LTR promoter activities (913-fold for the pREP-LTR(wt)-S-luc con-
struct [p < 0.0001] and 7.4-fold for the pREP-LTR(wt)-AS-luc construct [p = 0.0012]). Therefore, our results are 
consistent with the fact that the BLV 3′ LTR exhibits an antisense promoter activity and that this transcriptional 
activity is significantly higher (p = 0.0002) than the 5′ LTR sense promoter activity which is responsible for BLV 
mRNAs transcription.
To further characterize this newly identified promoter, we performed in silico analyses (YAPP Eukaryotic 
Core Promoter Predictor) of the BLV LTR sequence in the antisense orientation to identify specific cis-regulatory 
elements present in RNAPII-dependent promoters50. Our analyses revealed the presence of a putative BRE 
(nt 29–35, nt 1 defined as the first nucleotide of the 3′ LTR in antisense orientation), and overlapping MTE (nt 
94–105)/DPE (nt 100–104) motifs, that are both conserved in the nine different BLV genetic groups51.
In order to functionally characterize these cis-regulatory motifs, we introduced individually or in combi-
nation point mutations known to abolish the motif ’s function52,53 in the context of the pREP-LTR(wt)-AS-luc 
construct. The generated plasmids were transfected into the Raji cell line. Forty-hours post-transfection, cells 
were lysed and assayed for luciferase activity. Results presented in Fig. 7b showed that both mutations in the BRE 
and MTE/DPE motifs resulted in decreased luciferase activities compared to the promoter activity of the wild 
type LTR (p < 0.0001) suggesting a positive regulatory role of the BRE and MTE/DPE motifs in the BLV LTR 
antisense RNAPII-dependent promoter activity. Moreover, the combinatory mutation BRE-MTE/DPE resulted 
in a stronger decrease of the antisense promoter activity (p < 0.0001 compared to the reporter vectors containing 
the individual mutations in BRE and MTE/DPE) supporting the functional role of the identified motifs.
Taken together, our results demonstrate the presence of a transcriptionally active RNAPII promoter in the 
BLV 3′ LTR, associated with positive epigenetic marks and responsible for antisense transcription, a situation 
reminiscent of the previously reported HTLV-I 3′ LTR antisense promoter activity responsible for transcription 
of the viral hbz gene33.
Figure 6. The BLV miRNA cluster and 3′LTR/host genome junction are associated with active epigenetic 
marks. Chromatin prepared from L267 cells was immunoprecipitated with specific antibodies directed against 
different histone post-translational modifications (a,c), the H2A.Z histone variant (b) or with an IgG as 
background measurement. Purified DNA was then amplified with oligonucleotide primers hybridizing to the  
5′ LTR, the miRNA cluster or the 3′ LTR/host junction regions (a,c) or to the promoter regions of the ZNF12 and 
HOXD10 genes (b). Results are presented as histograms indicating percentages of immunoprecipitated DNA 
compared to the input DNA (% IP/INP). Data are the means ± SEM from one representative of at least three 
independent experiments.
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The RNAPIII collides the RNAPII at the BLV miRNA cluster. As presented in Fig. 1b, we showed an 
unexpected recruitment of RNAPII to the BLV miRNA cluster. As this presence could be explained by a coop-
erative binding32 or by the antisense transcription coming from the 3′ LTR (Fig. 7), we decided to investigate the 
RNAPII and RNAPIII coverage along the BLV genome by ChIP experiments followed by deep sequencing anal-
ysis. To this end, sonicated chromatin from L267 cells was immunoprecipitated with specific antibodies directed 
against the largest subunits of RNAPII (RPB1) and RNAPIII (RPC1) or with a purified IgG as background meas-
urement. The immunoprecipitated DNA was then used for paired-end deep sequencing analysis. Reads were 
aligned to the ovine reference genome, where BLV sequence has been inserted at the integration site of the L267 
cell line. Results of single-matched are presented in Fig. 8a.
As shown in Fig. 8a, we confirmed the presence of both RNAPII and RNAPIII complexes at the BLV miRNA 
cluster in agreement with our quantitative PCR results (Fig. 1b). Interestingly, our results revealed the presence 
of RNAPIII at the miRNA cluster, while RNAPII coverage was further downstream. This localization of RNAPII 
downstream relative to the RNAPIII transcriptional start site contrasted with previous studies showing coop-
eration between these two polymerases where RNAPII is present upstream the RNAPIII-dependent unit44,54. 
Therefore, our ChIP-seq data supports the evidence of an antisense RNAPII-dependent transcription initiating in 
the 3′ LTR. Moreover, there was a drastic drop in RNAPII ChIP-seq coverage at the miRNA cluster downstream of 
the RNAPIII coverage, further supporting convergent transcriptions and collision between RNAPIII and RNAPII 
(Fig. 8a). However, no recruitment of RNAPII to the 3′ LTR was observed. This result was due to the low quality 
of the read alignment in the LTRs and explained by the formation process of these LTRs during the reverse tran-
scription leading to regions with identical nucleotide sequences therefore avoiding unambiguous mapping of the 
reads. In order to have a better view of the RNAPII coverage at the different LTRs, we performed a new alignment 
of the reads allowing one or two matches to our reference genome. We decided to focus on unique DNA sequences 
comprising the regions adjacent to the LTRs boundaries (Fig. 8b). These results revealed a higher coverage of the 
3′ LTR/host junction, (22 and 2 reads covering the junction after chromatin immunoprecipitation with RNAPII 
antibody and IgG, respectively) compared to that of the 5′ LTR/viral genome junction (8 and 5 reads covering 
the junction after chromatin immunoprecipitation with RNAPII antibody and IgG, respectively). However, we 
showed that the coverage of the 3′ LTR/viral genome (5 and 0 reads covering the junction after chromatin immu-
noprecipitation with RNAPII antibody and IgG, respectively) and of the 5′ LTR/host genome (5 and 1 reads cover-
ing the junction after chromatin immunoprecipitation with RNAPII antibody and IgG, respectively) were similar.
Figure 7. The RNAPII promoter in the 3′LTR is transcriptionally active. Raji cells were transiently co-
transfected with (a) 400 ng of pREP-luc, pREP-LTR(wt)-S-luc or pREP-LTR(wt)-AS-luc constructs, increasing 
amounts of an expression vector for Tax (50 or 150 ng of plasmid DNA) and 20 ng of pRL-TK or with (b) 
400 ng of pREP-luc, pREP-LTR(wt) -AS-luc or pREP-LTR(MTE/DPE*)-AS-luc, pREP-LTR(BRE*)-AS-luc or pREP-
LTR(MTE/DPE* & BRE*)-AS-luc mutated constructs and 20 ng of pRL-TK. Forty-eight hours after transfection, cells 
were collected, lysed and both firefly and renilla luciferase activities were measured. Results are presented as 
histograms indicating relative luciferase activities compared to the pREP-luc for wich a value of 1 was assigned. 
Data are the mean ± SEM from one representative of at least three independent experiments.
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Altogether, our data are further confirming RNAPII recruitment to the transcriptional promoter located at the 
end of the 3′ LTR (Fig. 8b) and indicate the presence of an active RNAPII-dependent promoter in the BLV 3′ LTR, 
responsible for an antisense transcription and colliding with the RNAPIII transcribing the viral miRNA cluster.
Discussion
One of the major features of BLV infection is the absence of viremia due to the RNA polymerase II 5′ LTR-driven 
transcriptional repression. Nevertheless, recent reports using bioinformatics analysis26 and high throughput 
sequencing of small RNAs from BLV-infected cells27 have shown the presence of a cluster coding for viral miRNAs 
located between the end of env gene and the pX region. Some evidence support the notion that the miRNA cluster 
is transcribed by the RNA polymerase III, although a direct functional link between RNAPIII transcriptional 
activity and BLV miRNAs expression has not been reported to date. Indeed, the algorithm used by Kincaid and 
coworkers has been designed to find RNAPIII-specific initiation cis-regulatory elements that have been func-
tionally characterized30, in the genome of retroviruses and this analysis has identified BLV as the only retrovirus 
containing such cis-regulatory elements26. Moreover, α -amanitin treatment at a concentration known to inhibit 
specifically RNAPII but not RNAPIII transcriptional elongation55 did not affect BLV miRNA expression26,27,30. In 
the present report, we aimed at providing a direct demonstration that the RNAPIII is responsible for BLV miRNA 
transcription and is recruited to the viral miRNA cluster in vivo, and at epigenetically and functionally character-
izing its promoter. To this end, we performed chromatin immunoprecipitation assays in two BLV latently-infected 
ovine cell lines and in BLV-infected primary B cells.
We firstly demonstrated that all tested RNAPIII subunits were recruited to the miRNA cluster in vivo 
(Fig. 1b,d), supporting the presence of a bona fide RNAPIII at this genomic region in the context of a complete 
BLV provirus and confirming previous evidence26,27,30. Furthermore, we also demonstrated the recruitment of 
the RPC1 RNAPIII subunit in primary PBMCs from a BLV-infected leukemic sheep suffering from leukemia 
(Fig. 1c), confirming our results in a more physiological model of BLV infection. We also showed that RNAPIII 
recruitment to the miRNA cluster was not affected by induction of 5′ LTR-dependent viral expression either by 
ectopic expression of TaxBLV (L267LTaxSN cell line) or by PMA/ionomycin treatment (Fig. 1f). These data suggest 
that the level of 5′ LTR transcriptional activity does not seem to influence the recruitment of RNAPIII, in agree-
ment with the stable level of miRNA expression previously observed in L267LTaxSN cells compared to L267 cells27. 
After confirming the in vivo recruitment of RNAPIII to the BLV miRNA cluster, we showed that the viral miRNA 
expression was significantly decreased upon depletion of RPC6 (Fig. 2b,c), a specific RNAPIII subunit impli-
cated in RNAPIII transcriptional initiation36, functionally demonstrating that the BLV miRNAs are transcribed 
by RNAPIII. Moreover, two forms of mammalian RNAPIII (α or β ) have been identified depending on the pres-
ence of RPC7α or RPC7β subunit isoforms, respectively41,42. While the RNAPIIIβ is essential for undifferentiated 
and differentiated cells, the RNAPIIIα is mainly present in undifferentiated and tumor cells, and the level of the 
RPC7α mRNA increases during cellular transformation42. Interestingly, we showed here that both isoforms of 
RPC7 were recruited to the miRNA cluster (Fig. 4), suggesting that BLV miRNAs are transcribed by the two forms 
and do not require cellular transformation. Our results are in agreement with previously reported RNA-seq data27.
Compared to the promoter complexity of RNAPII transcribed genes, the promoter driving RNAPIII tran-
scribed genes is much more simple. Indeed, RNAPIII promoters are composed of a relatively small number of 
cis-acting elements that are generally located within the transcriptional unit, and regulated by a small number 
of transcription factors (reviewed in ref. 39). In this study, we showed that the TFIIIA initiation factor, which is 
specific of type 1 RNAPIII promoter driving transcription of the 5S rDNA, was not recruited to the BLV miRNA 
cluster. However, we demonstrated that the TFIIIB (composed of TBP, BDP1 and BRF1) and TFIIIC complexes 
were present at the miRNA cluster, supporting the use of a canonical type 2 RNAPIII promoter for BLV miRNA 
transcription (Fig. 3a) as for cellular tRNA transcription. These results confirm the prediction of the algorithm, 
based on cis-regulatory elements, used by Kincaid and co-workers26.
Our laboratory has previously demonstrated that DNA methylation and histone tail post-translational modifi-
cations are important epigenetic chromatin modifications regulating BLV gene expression19,21,25. Indeed, we have 
previously reported that 5′ LTR hypermethylation is associated with the BLV repression in the true latent L267 
cell line but not in the defective latency state present in the YR2 cell line25. Here, we showed by bisulfite genome 
sequencing that the DNA encoding the BLV miRNA cluster, which is located within a CpG island, was not meth-
ylated. To further characterize the epigenetic landscape associated with the miRNA cluster, we demonstrated the 
absence of repressive epigenetic marks (H3K9me3 and H3K27me3) and the presence of epigenetic marks asso-
ciated with RNAPII- and RNAPIII-dependent active promoters44,45. More specifically, we showed the presence 
of acetylated histone H3 (H3Ac, H3K9Ac), di-and tri-methylated lysine 4 histone H3 (H3K4me2, H3K4me3). 
Overall, the activating chromatin environment of the miRNA cluster we demonstrated in the BLV latently-infected 
cell lines were consistent with the high level of expression of the miRNAs observed in RNA-seq experiments27.
The ChIP results presented here showed an in vivo recruitment of RNAPII at the 3′ LTR/host junction 
(Fig. 1b). This specific recruitment was associated with the presence of positive epigenetic marks (such as histone 
acetylation, H3K4me2, H3K4me3 and the H2A.Z histone variant) and the absence of repressive marks (such 
as H3K9me3, H3K27me3 (Fig. 6a) or DNA methylation25). Moreover, using episomally replicating luciferase 
reporter constructs that display the hallmarks of proper chromatin structure when transiently transfected into 
cells48,49, we demonstrated that the BLV 3′ LTR exhibited an antisense promoter activity. BLV 3′ LTR antisense 
promoter activity reported here is further supported by the presence of H3K36me3 along the BLV provirus that 
is lower at the 3′ LTR/host junction than at the miRNA cluster and the 5′ LTR. Indeed, H3K36me3 level gen-
erally increases along RNAPII transcribed regions45, whereas RNAPIII transcribed genes lack for enrichment 
of this epigenetic mark44. In addition, RNA-seq experiments of primary tumors and pre-leukemic clones from 
BLV infected animals identified the production of two viral antisense transcripts originating in the BLV 3′ LTR56. 
Interestingly, the transcriptional start site (TSS) for these antisense transcripts corresponds to the TSS predicted 
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by the position of the BRE and MTE/DPE motifs that we identified (Fig. 7b). The identification of a promoter 
at the end of the BLV 3′ LTR could be the counterpart of the previously reported antisense RNAPII promoter 
responsible for transcription of the hbz gene in the closely related HTLV-1 deltaretrovirus33. Several studies have 
previously demonstrated the critical role of HBZ expression in HTLV-1-mediated oncogenesis. Indeed, HBZ has 
been shown to increase HTLV-1-infected T cells proliferation and to inhibit signaling pathways such the AP-1 
and NF-κB signaling pathways57. Moreover, HBZ also contributes to HTLV-1 escape from the host immune sys-
tem by counteracting Tax functions and therefore by reinforcing viral 5′ LTR silencing58. In the context of BLV 
pathogenesis, the antisense transcription originating from this newly discovered promoter could play similar 
roles in infected B cells proliferation and in the BLV latency. In addition, the antisense transcription could gener-
ate small interfering RNAs leading to the cleavage of BLV mRNAs, therefore ensuring the establishment of viral 
latency and preventing viral reactivation and detection of the infected cells by the host immune system.
It has been shown that α -amanitin treatment, an inhibitor of RNAPII transcriptional elongation when used 
at low concentration55 does not decrease BLV miRNAs expression26,27, thereby indicating that RNAPII is not 
responsible for the BLV miRNAs transcription. Nevertheless, we showed here the recruitment of RNAPII to the 
miRNA cluster (Fig. 1b). It is worth noting that Barski and coworkers have previously shown the presence of 
RNAPII at RNAPIII-transcribed loci by ChIP-seq experiments44. In addition, it has been proposed that RNAPII 
activity might facilitate the expression of some RNAPIII products by modifying the local chromatin structure54. 
However, in the context of the BLV provirus, our ChIP-seq experiments suggest that the presence of RNAPII at 
the miRNA cluster is the result of a collision phenomenon between RNAPIII transcribing the BLV miRNAs in 
the sense orientation and RNAPII transcribing from the 3′ LTR in the antisense orientation (Fig. 8a,b). It has been 
previously demonstrated in vitro that collided RNAPII polymerases resulting from convergent transcription can 
stop without dissociation from the genomic unit59. A similar phenomenon could therefore explain the in vivo 
Figure 8. Collision between RNAPIII and RNAPII at the BLV miRNA cluster. View of the tags obtained 
following ChIP experiments using chromatin prepared from L267 cells and immunoprecipitated with specific 
antibodies raised against the largest subunit of the RNA polymerase II (RPB1), the largest subunit of the RNA 
polymerase III (RPC1) or with a purified IgG as background measurement. (a) Single matched reads for 
RNAPII/RNAPIII coverage along the BLV genome. (b) Zoom-in of the 5′ and 3′ LTRs regions for single and 
double matched reads.
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RNAPII recruitment we observed here in our ChIP and ChIP-seq experiments (Figs 1b and 8a). Nevertheless, 
to date, the biological role of convergent transcriptions remains largely unknown. Some studies have shown that 
antisense transcription could be involved in the masking of splicing sites and thus responsible for the production 
of different transcript isoforms60, whereas other studies have shown that sense and antisense transcriptions can 
be parts of a self-regulatory circuit allowing a fine-tuned regulation between their respective expression61. In the 
context of the BLV provirus, the collision between the two polymerase complexes could affect both RNAPIII 
and RNAPII transcriptions. Indeed, it has been previously shown that the negative modulation of BLV miRNAs 
transcription results in an increase of the antisense transcription56. Alternatively, it has been shown that the AS1-S 
harbors a weak termination signal with a canonical polyA sequence, just before the miRNA cluster, but without 
an adjacent GU-rich consensus56. Therefore, the collision between RNAPII transcribing in the antisense orien-
tation from the 3′ LTR and RNAPIII transcribing the viral miRNAs could increase the transcription termination 
efficiency and favor a better release of the AS1-S transcript.
In conclusion, our data demonstrated a direct functional link between RNAPIII transcriptional activity and 
BLV miRNAs expression, and the in vivo recruitment of a bona fide RNAPIII complex to the BLV miRNA cluster 
through a canonical type 2 RNAPIII promoter in BLV-latently infected cell lines and ovine BLV-infected primary 
cells. Moreover, we demonstrated that the BLV LTR was able to drive transcription in the antisense orientation from 
a newly identified RNAPII-dependent promoter located at the end of the LTR, as previously reported for the closely 
related HTLV-1 retrovirus. Importantly, our ChIP and ChIP-seq experiments demonstrated a high RNAPIII recruit-
ment peak in the BLV micro-RNA cluster and an RNAPII recruitment peak just downstream of this region, suggest-
ing a collision phenomenon between the two polymerases and stalling of RNAPII. The two newly identified RNAPIII 
and RNAPII transcriptional promoters located in the BLV genome brings additional factors in an already complex 
network of regulators affecting the level of BLV expression and potentially deltaretrovirus induced leukemia.
Methods
Cell lines and cell culture. L267 is a clonal lymphoma-derived B-cell line established from a BLV-infected 
sheep (S267) injected with naked proviral DNA of an infectious BLV variant62, whose provirus displays a wild-
type sequence23,63. The L267LTaxSN cell line results from the transduction of native L267 with the pLTaxSN retro-
viral vector expressing the tax cDNA following co-cultivation with the PG13LTaxSN producer cell line and G418 
selection of transduced cells34,63. YR2 is a cloned B-lymphoid cell line established from peripheral blood lympho-
cytes (PBLs) isolated from a BLV-infected sheep64, containing a single monoclonally integrated mutated silent 
provirus5,34. These cell lines were maintained in Opti-MEM medium (Life Technologies) supplemented with 10% 
FBS, 1 mM sodium pyruvate, 2 mM glutamine, non-essential amino acids and 100 μ g/ml kanamycin. The 293T 
cell line (CRL-3216), obtained from American Type Culture Collection (ATCC, Manassas, VA), is established 
from human embryonic kidney cells that express the large T antigen of simian virus 40 [SV40]65). This cell line 
was maintained in DMEM medium (Life Technologies) supplemented with 10% FBS, 1 mM sodium pyruvate 
and 1% of penicillin-streptomycin. The Raji cell line66, a human B-lymphoid Epstein-Barr virus-positive cell line 
derived from a Burkitt’s lymphoma obtained from the AIDS Research and Reference Reagent Program (National 
Institute of Allergy and Infectious Disease [NIAID], National Institute of Health [NIH]), was maintained in RPMI 
1640-Glutamax I medium (Life Technologies) supplemented with 10% FBS and 1% of penicillin-streptomycin. 
All the cells were grown at 37 °C in a humidified 95% air/5% CO2 atmosphere. Frozen primary ovine PBMCs were 
kindly provided by Anne Van den Broeke (Unit of Animal Genomics, GIGA-R, University of Liège, Belgium).
Plasmid constructs. The eukaryotic expression vectors pTax is a gift from Drs. Luc Willems and Richard 
Kettmann15. TRC Lentiviral shRNA plasmids (pLKO.1) against RPC6 and non-targeting control shRNA were 
purchased from Dharmacon and Sigma-Aldrich, respectively. The pVSG-G and the psPAX2 packaging vectors 
were obtained from the Reference Reagent Program. To construct the episomally replicating constructs, a 
fragment containing the luciferase gene and the simian virus 40 (SV40) late poly(A) signal was prepared from 
pGL3-BASIC (Promega) by digestion with KpnI, blunt-ended with DNA polymerase I large (Klenow) fragment, 
and digestion with BamHI, successively. This fragment was cloned into pREP10s19 digested with PvuII and 
BamHI. The resulting plasmid was designed pREP-luc. A fragment containing the complete LTR of the 344 BLV 
provirus was isolated from the non episomal pLTRwt-luc10 by digestion with SmaI. This fragment was cloned in 
both orientations in the pREP-luc digested with BglII and blunt-ended to obtain the pREP-LTR(wt)-S-luc and 
pREP-LTR(wt)-AS-luc. The pLTRwt-luc10 construct was used as a substrate for mutagenesis (by the QuickChange 
Site-directed Mutagenesis method, Stratagene). Different mutations were generated with pairs of mutagenic oli-
gonucleotide primers (described in Supplementary Table S1). Mutated LTRs were fully sequenced after identifi-
cation and cloned in pREP10s as described above.
To construct the plasmid expressing the BLV miRNAs, genomic DNA from the L267 cell line was firstly 
extracted using the DNeasy Blood and Tissue kit (Qiagen) according to the protocol of the manufacturer. The 
miRNA cluster was then amplified by PCR using specific primers (Supplementary Table S1) and 125 ng of 
genomic DNA. This PCR reaction was performed at 95 °C for 5 min followed by 35 cycles at 95 °C for 30 sec, 
50 °C for 1 min 30 sec and by 60 °C for 7 min. The obtained product was purified on an agarose gel, cloned in the 
pBS-SKP vector (Promega) and sequenced in order to verify the absence of mutation.
Chromatin Immunoprecipitation assays. ChIP assays were performed as previously described25 
using the ChIP assay kit (EMD Millipore). Briefly, cells were cross-linked for 10 min at room temperature with 
1% formaldehyde and their chromatin were sonicated (Bioruptor Plus, Diagenode) to obtain DNA fragments 
of 200–400 bp. Chromatin immunoprecipitations were performed with chromatin from 6 106 cells (1 106 from 
the epigenetic modifications) and 5 μ g of antibodies (see Supplementary Table S2). Quantitative real-time PCR 
reactions were performed using 1/60e of the immunoprecipitated DNA and the PerfeCTa SYBRgreen SuperMix 
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(Quanta BioSciences). Relative quantification using standard curve method was performed for each primer pair 
and 96-well Optical Reaction plates were read in a StepOnePlus PCR instrument (Applied Biosystem). Fold enrich-
ments were calculated as percentages of input values or as fold inductions relative to the values measured with IgG. 
Primer sequences used for quantification (see Supplementary Table S3) were designed using the software Primer 3.
ChIP-sequencing assays. ChIP assays were performed as described above. Recovered DNA (~100 ng) was 
then used for library preparation using the TruSeq ChIP Sample Preparation protocol following Manufacter’s 
instructions (Illumina Technologies). Paired-end sequencing was then performed with the Illumina HiSeq 2000 
instrument. More than 20 millions of single reads were obtained for RPC1 and RPB1 libraries and 10 millions 
of single reads for IgG library. The single-matched reads were mapped to an hybrid ovine genome (OAR v3.1) 
containing the BLV provirus sequence (GenBank: KT122858.1) at the L267 integration site (chr10:86299813) 
using bowtie2 software (-N 1 and -k 5 parameters). Finally, our results were visualized using IGV program. Reads 
spanning LTR-host and LTR-BLV boundaries were extracted from the alignment file using an in-house R script 
and ggplot2 was used to plot the ChIP-seq coverage.
Bisulfite-mediated methylcytosine mapping. Genomic DNA was isolated from L267 and YR2 cell lines 
using the DNeasy Blood and Tissue kit (Qiagen) according to the protocol of the manufacturer. One microgram 
of genomic DNA was treated with bisulfite with EpiTect Bisulfite kit (Qiagen). The miRNA cluster region of BLV 
provirus was amplified by two successive PCR reactions (primer sequences are in the Supplementary Table S1). 
The first PCR reaction was performed at 95 °C for 5 min followed by 35 cycles at 95 °C for 30 sec, 50 °C for 1 min 
30 sec and by 60 °C for 7 min. The second PCR reaction was performed at 95 °C for 5 min followed by 40 cycles at 
95 °C for 30 sec, 50 °C for 1 min, 72 °C for 1 min 30 sec and by 7 min at 72 °C. The obtained product was purified 
on an agarose gel and cloned in the pGEM-T easy vector (Promega). At least, 10 clones from each condition were 
sequenced and analyzed to identify methylated CpGs dinucleotide in this viral region by MethTools software. The 
frequency of conversion of C to T following sodium bisulfite treatment was greater than 98% at non-CpG sites, 
indicating the adequacy of the approach.
RNA purification and analysis of transcripts. Total RNA from 3 106 cells was extracted using TRIzol 
(Life Technologies) followed by treatment with turbo DNAse (Life Technologies) according to the manufactur-
er’s protocol. Retrotranscription reactions were performed with PrimeScript RT-PCR Kit (TaKaRa) either using 
200 ng of RNA and random hexamer oligonucleotides (for luciferase and GAPDH genes) or specific stemloop 
oligonucleotides for miRNA quantification67 (Supplementary Table S1). cDNA was then quantified by real-time 
PCR as described above (primer sequences are presented in Supplementary Table S3).
Lentiviral production. VSV-G pseudotyped lentiviral particles were produced by transfection of 293T cells 
(5 106 /10 cm dish), with the different shRNAs-containing plasmids (9 μ g), the pVSV-G (2.25 μ g) and the psPAX2 
(6.75 μ g) packaging vectors by the calcium phosphate transfection method according to the manufacturer’s pro-
tocol (Promega). 72 hours post-transfection, viral stocks were collected.
Transduction assays. 293T cells (4.5 105) were transduced in 6-well plates by 1 mL of undiluted viral stock 
supplemented by Polybrene at the final concentration of 8 μ g/mL. 6 hours post-transduction, the medium was 
removed and replaced by 2 mL of complete DMEM.
Transient transfection and luciferase assays. 293T cells (4.5 105) were transfected with 3 μ g of DNA 
(pmiR and pTK-luc) using FuGENE 6 reagent (Promega) according to the manufacturer’s protocol in 6-well 
plates. Raji cells (3 106) were transfected with 750 ng of DNA (pREP-luc constructs, pTAX and pGL4.74 (Promega) 
as internal control) using the DEAE-dextran procedure as described previously19. 48 h post-transfection, cells 
were collected, lysed and luciferase activities were measured. Firefly luciferase values were normalized with 
respect to the Renilla luciferase values using the DualGlo-luciferase reporter assay system (Promega).
Western blot experiments. Western blotting were performed with 10 μ g of the total protein extracts. The 
immunodetection was assessed using antibodies targeting RPC6 or the α -tubulin (Supplementary Table S2) as 
loading control. Quantifications of both the RPC6 and the α -tubulin intensities were performed with the ImageJ 
software (National Institutes of Health, NIH).
Statistical analysis. Data sets from transfection experiments were analyzed using a two-way ANOVA with 
log-transformed value to ensure homogeneous standard deviation, followed by paired comparisons between 
samples (Tukey’s test). Data sets from RNA quantifications were analyzed using a two-tailed unpaired T test 
comparisons between samples and the cells transfected with the non-targeting shRNA. The threshold of statistical 
significance α was set at 0.05. Analyses were performed using Prism version 6.0 (GraphPad software).
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